Drug discovery company LabGenius Therapeutics announced on Thursday a new collaboration with French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) to optimise therapeutic NANOBODY proteins for multiple targets using LabGenius' machine learning-driven antibody discovery platform, EVA.

The partnership leverages LabGenius' AI and high-throughput experimentation capabilities alongside Sanofi's expertise in NANOBODY development to co-optimise proteins for therapeutic properties.

This marks the second collaboration between the companies, following the success of their initial programme.

The new initiative will focus on multiple targets in the area of inflammation, aiming to enhance the design and efficacy of potential therapeutics.

LabGenius' CSO, Dr. Angus Sinclair, said that this collaboration validates the platform's ability to address complex antibody co-optimisation challenges across diverse therapeutic areas.

The partnership is designed to accelerate drug discovery and improve outcomes for patients by combining advanced machine learning with established antibody development expertise.